Skip to main content

Advertisement

Table 3 SPM risk associated with combined FAS/FASL variant genotypes after index OPC and non-OPC

From: Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck

No. variant genotypes OPC Non-OPC cHRsa (95 % CI), P aHRs (95 % CI)b, P
SPM/SPM-free (42/710) SPM/SPM-free (n = 82/695) OPC Non-OPC OPC Non-OPC
 0-1 (ref.) 5/142 10/132 1.0 1.0 1.0 1.0
 2 15/256 27/264 1.3 (0.4–3.5), 0.673 1.4 (0.6–2.7), 0.585 1.3 (0.5–3.7), 0.698 1.5 (0.5–3.3), 0.612
 3 16/220 31/229 1.6 (0.6–4.1), 0.587 1.8 (0.9–3.5), 0.061 1.7 (0.5–3.8), 0.632 1.8 (1.0–3.9), 0.051
 4 6/92 14/70 2.2 (0.9–6.8), 0.112 2.7 (1.2–6.1), 0.014 2.0 (0.9–6.6), 0.110 2.2 (1.2–6.5), 0.021
  1. aCrude HRs
  2. bHRs were adjusted for age, sex, ethnicity, smoking, alcohol, index cancer stage, and treatment